The relationship between glycemic variability and diabetic peripheral neuropathy in type 2 diabetes with well-controlled HbA1c

被引:133
作者
Xu, Feng [1 ]
Zhao, Li-hua [1 ]
Su, Jian-bin [1 ]
Chen, Tong [2 ]
Wang, Xue-qin [1 ]
Chen, Jin-feng [1 ]
Wu, Gang [1 ]
Jin, Yan [1 ]
Wang, Xiao-hua [1 ]
机构
[1] Nantong Univ, Affiliated Hosp 2, Dept Endocrinol, Nantong 226001, Peoples R China
[2] Nantong Univ, Affiliated Hosp 2, Dept Clin Lab, Nantong 226001, Peoples R China
关键词
Glycemic variability; Continuous glucose monitoring; Diabetic peripheral neuropathy; Type; 2; diabetes; CHRONIC HYPERGLYCEMIA; GLUCOSE VARIABILITY; COMPLICATIONS; PREVALENCE; FLUCTUATIONS; ASSOCIATION; HEMOGLOBIN; SEVERITY; DISEASE; IMPACT;
D O I
10.1186/1758-5996-6-139
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Background: Diabetic peripheral neuropathy (DPN) is one of the most common microvascular complications of diabetes. Glycemic variability could be an independent risk factor for diabetes complications in addition to average glucose. Type 2 diabetes with well-controlled glycosylated hemoglobin A1c (HbA1c) may have different terms of glycemic variability and vascular complication consequences. The aim of the study is to investigate the relationship between glycemic variability and DPN in type 2 diabetes with well-controlled HbA1c (HbA1c < 7.0%). Methods: 45 type 2 diabetes with well-controlled HbA1c(HbA1c < 7.0%) and with DPN (DM/DPN group) were recruited in the study, and 45 type 2 diabetes with well-controlled HbA1c and without DPN (DM/-DPN group) were set as controls. The two groups were also matched for age and diabetic duration. Blood pressure, body mass index (BMI), insulin sensitivity index (Matsuda index, ISI), total cholesterol (TC), triglyceride (TG), high density lipoprotein cholesterol (HDLC), and low density lipoprotein cholesterol (LDLC) were tested in the two groups. And all patients were monitored using the continuous glucose monitoring (CGM) system for consecutive 72 hours. The multiple parameters of glycemic variability included the standard deviation of blood glucose (SDBG), mean of daily differences (MODD) and mean amplitude of glycemic excursions (MAGE). Results: The DM/DPN group had a greater SDBG, MODD and MAGE, when compared to the DM/-DPN group (p < 0.05). BMI, TC, and LDLC of DM/DPN group were lower than those of DM/-DPN group (p < 0.05). The patients with hypoglycemia were comparable between the two groups (p > 0.05). Univariate analysis showed DPN was closely associated with BMI (OR 0.82, CI 0.72-0.94, p = 0.005), TC (OR 0.63, CI 0.42-0.93, p = 0.02), LDLC (OR 0.4, CI 0.20-0.80, p = 0.009), SDBG (OR 2.95, CI 1.55-5.61, p = 0.001), MODD (OR 4.38, CI 1.48-12.93, p = 0.008), MAGE (OR 2.18, CI 1.47-3.24, p < 0.001). Multivariate logistic regression analysis showed that MAGE (OR 2.05, CI 1.36-3.09, p = 0.001) and BMI (OR 0.85, CI 0.73-0.99, p = 0.033) were significantly correlating with DPN. Glycemic variability, evaluated by MAGE, was the most significantly independent risk factor for DPN. Conclusions: There was a close relationship between glycemic variability evaluated by MAGE and DPN in type 2 diabetes with well-controlled HbA1c.
引用
收藏
页数:7
相关论文
共 39 条
[1]  
Amer Diabet Assoc, 2012, DIABETES CARE, V35, pS64, DOI [10.2337/dc19-S002, 10.2337/dc12-S064, 10.2337/dc23-S002, 10.2337/dc09-S062, 10.2337/dc18-S002]
[2]   Response to comment on: American Diabetes Association. Standards of medical care in diabetes-2011 (vol 34, pg e54, 2011) [J].
Wysham, C. H. ;
Kirkman, M. S. .
DIABETES CARE, 2011, 34 (08) :1887-1887
[3]   Diabetic neuropathies - A statement by the American Diabetes Association [J].
Boulton, AJM ;
Vinik, AI ;
Arezzo, JC ;
Bril, V ;
Feldman, EL ;
Freeman, R ;
Malik, RA ;
Maser, RE ;
Sosenko, JM ;
Ziegler, D .
DIABETES CARE, 2005, 28 (04) :956-962
[4]   Diabetic somatic neuropathies [J].
Boulton, AJM ;
Malik, RA ;
Arezzo, JC ;
Sosenko, JM .
DIABETES CARE, 2004, 27 (06) :1458-1486
[5]   Glycemic variability:: A hemoglobin A1c-independent risk factor for diabetic complications [J].
Brownlee, M ;
Hirsch, IB .
JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION, 2006, 295 (14) :1707-1708
[6]   Biochemistry and molecular cell biology of diabetic complications [J].
Brownlee, M .
NATURE, 2001, 414 (6865) :813-820
[7]   The pathobiology of diabetic complications - A unifying mechanism [J].
Brownlee, M .
DIABETES, 2005, 54 (06) :1615-1625
[8]   Prevalence and the associated burden of illness of symptoms of diabetic peripheral neuropathy and diabetic retinopathy [J].
Candrilli, Sean D. ;
Davis, Keith L. ;
Kan, Hong J. ;
Lucero, Melanie A. ;
Rousculp, Matthew D. .
JOURNAL OF DIABETES AND ITS COMPLICATIONS, 2007, 21 (05) :306-314
[9]   Can motor nerve conduction velocity predict foot problems in diabetic subjects over a 6-year outcome period? [J].
Carrington, AL ;
Shaw, JE ;
Van Schie, CHM ;
Abbott, CA ;
Vileikyte, L ;
Boulton, AJM .
DIABETES CARE, 2002, 25 (11) :2010-2015
[10]  
Hay L C, 2003, Diabetes Technol Ther, V5, P19, DOI 10.1089/152091503763816427